Adverse events leading to trial discontinuation were 2.6% ... or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). 7 Semaglutide is not approved for the treatment of adults with MASH.

Adverse events leading to trial discontinuation were 2.6% ... or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).7 Semaglutide is not approved for the treatment of adults with MASH.

GLP-1 receptor agonists remain blockbuster drugs for weight management for people with overweight or obesity. Increasingly, ...

Yvette C. Terrie, RPh, and Danielle Green, RDN, discuss the obesity epidemic and the many benefits of a holistic approach to ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE phase 3 clinical trial published today in the New England Journal of ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...